文献速递炎症性肠病

炎症性肠病炎症的活检与血液分子生物标志物

Biopsy and blood-based molecular biomarker of inflammation in IBD.
PubMed 文献 · Gut · 2022-09-15

基于Mount Sinai克罗恩病与结肠炎登记库中712例内镜下定义的炎症活检与1778例非炎症活检的转录组分析,构建了分子炎症评分bMIS及循环MIS(cirMIS),并在四个独立IBD队列中验证其与临床、内镜及组织学活动指数的关联,显示其可更深层量化肠道炎症并可能预测治疗应答与疾病复发。

要点

  • bMIS/cirMIS与临床、内镜及组织学疾病活动指数强相关。
  • 组织学炎症评分相同的患者bMIS评分可变,提示bMIS可描述更深层炎症范围。
  • 在现有临床试验数据集中,两评分对IBD治疗有反应性。

核心结论

  • 基于转录组的评分提供了肠道炎症的替代客观且更深层的量化方法,可补充当前用于疾病监测的临床评估,并可能预测治疗应答及疾病复发风险较高的患者。

研究设计与样本

  • 对Mount Sinai克罗恩病与结肠炎登记库中712例内镜下定义的炎症活检和1778例非炎症活检(498例克罗恩病、421例溃疡性结肠炎和243例对照)进行转录组分析,以识别差异表达基因并通过基因集方差分析生成分子炎症评分bMIS。
  • 利用血液转录组数据生成反映肠道分子炎症的循环MIS(cirMIS)评分。
  • 在四个独立IBD队列中验证bMIS/cirMIS作为肠道炎症指标的效能。

主要发现

  • bMIS/cirMIS与临床、内镜及组织学疾病活动指数强相关。
  • 组织学炎症评分相同的患者bMIS评分可变,表明bMIS描述了更深层的炎症范围。
  • 在现有临床试验数据集中,两评分均对IBD治疗有反应性。
  • 尽管基线内镜和组织学活动度相似,基线bMIS水平较低的UC患者相比水平较高者更可能为治疗应答者。
  • 在内镜和组织学缓解的UC患者中,bMIS水平较低者随时间推移发生疾病复发的可能性较小。

关键数值与推荐

  • bMIS通过基因集方差分析生成。
  • cirMIS利用血液转录组数据生成。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: IBD therapies and treatments are evolving to deeper levels of remission. Molecular measures of disease may augment current endpoints including the potential for less invasive assessments. DESIGN: Transcriptome analysis on 712 endoscopically defined inflamed (Inf) and 1778 non-inflamed (Non-Inf) intestinal biopsies (n=498 Crohn's disease, n=421 UC and 243 controls) in the Mount Sinai Crohn's and Colitis Registry were used to identify genes differentially expressed between Inf and Non-Inf biopsies and to generate a molecular inflammation score (bMIS) via gene set variance analysis. A circulating MIS (cirMIS) score, reflecting intestinal molecular inflammation, was generated using blood transcriptome data. bMIS/cirMIS was validated as indicators of intestinal inflammation in four independent IBD cohorts. RESULTS: bMIS/cirMIS was strongly associated with clinical, endoscopic and histological disease activity indices. Patients with the same histologic score of inflammation had variable bMIS scores, indicating that bMIS describes a deeper range of inflammation. In available clinical trial data sets, both scores were responsive to IBD treatment. Despite similar baseline endoscopic and histologic activity, UC patients with lower baseline bMIS levels were more likely treatment responders compared with those with higher levels. Finally, among patients with UC in endoscopic and histologic remission, those with lower bMIS levels were less likely to have a disease flare over time. CONCLUSION: Transcriptionally based scores provide an alternative objective and deeper quantification of intestinal inflammation, which could augment current clinical assessments used for disease monitoring and have potential for predicting therapeutic response and patients at higher risk of disease flares.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Argmann C, Hou R, Ungaro RC, et al. Biopsy and blood-based molecular biomarker of inflammation in IBD. Gut. 2022. PMID: 36109152. doi:10.1136/gutjnl-2021-326451

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。